400565
doi
10.1186/s13024-017-0162-3
oai:zenodo.org:400565
user-inmind
user-eu
Lemoine, Laetitia
Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Novum 5th floor, 141 57 Huddinge, Sweden
Chiotis, Konstantinos
Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Novum 5th floor, 141 57 Huddinge, Sweden
Leuzy, Antoine
Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Novum 5th floor, 141 57 Huddinge, Sweden
Rodriguez-Vieitez, Elena
Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Novum 5th floor, 141 57 Huddinge, Sweden
Nordberg, Agneta
Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Novum 5th floor, 141 57 Huddinge, Sweden and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
Tau PET imaging: present and future directions.
Saint-Aubert, Laure
Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Novum 5th floor, 141 57 Huddinge, Sweden
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Biomarker
Clinical research
Neurodegenerative diseases
Positron emission tomography imaging
Tau
Tracer development
<p>Abnormal aggregation of tau in the brain is a major contributing factor in various neurodegenerative diseases. The role of tau phosphorylation in the pathophysiology of tauopathies remains unclear. Consequently, it is important to be able to accurately and specifically target tau deposits in vivo in the brains of patients. The advances of molecular imaging in the recent years have now led to the recent development of promising tau-specific tracers for positron emission tomography (PET), such as THK5317, THK5351, AV-1451, and PBB3. These tracers are now available for clinical assessment in patients with various tauopathies, including Alzheimer's disease, as well as in healthy subjects. Exploring the patterns of tau deposition in vivo for different pathologies will allow discrimination between neurodegenerative diseases, including different tauopathies, and monitoring of disease progression. The variety and complexity of the different types of tau deposits in the different diseases, however, has resulted in quite a challenge for the development of tau PET tracers. Extensive work remains in order to fully characterize the binding properties of the tau PET tracers, and to assess their usefulness as an early biomarker of the underlying pathology. In this review, we summarize recent findings on the most promising tau PET tracers to date, discuss what has been learnt from these findings, and offer some suggestions for the next steps that need to be achieved in a near future.</p>
Zenodo
2017-02-20
info:eu-repo/semantics/article
791935
user-inmind
user-eu
award_title=Imaging of Neuroinflammation in Neurodegenerative Diseases; award_number=278850; award_identifiers_scheme=url; award_identifiers_identifier=https://cordis.europa.eu/projects/278850; funder_id=00k4n6c32; funder_name=European Commission;
1579524675.41668
1602049
md5:7c77ed4ac5db238aa11917d7a6534b73
https://zenodo.org/records/400565/files/Saint-Aubert_MolNeurodegener_2017-P12b.pdf
public
Molecular Neurodegeneration
12
1
19
2017-02-20